Thanks for choosing mmm-online.com Sign up for your FREE account now and join the thousands of other healthcare marketing professionals who rely on us for all the latest industry news and innovative ideas for direct and digital strategy. Simply fill out the fields below.

Keep me logged in Forgot your password?

Please wait...

Please wait...

DevicePharm

2100 Main Street
Suite 250
Irvine, CA 92677
Tel: 949-271-1180
Fax: 949-271-1198
Web Site: www.devicepharm.com
Email: info@DevicePharm.com
Founded: 2002

Officers: Clay Wilemon, CEO & Chief Strategy Officer; John Hermie, President

2011 Gross Income: $10 million to $15 million

Full Time Employees: 23 (2011) 22 (2010)

Healthcare Accounts: Serves over 30 healthcare clients including: Abbott Medical Optics, Abbott Molecular, Avantis Medical Systems, Baxter Biosurgery, Cianna Medical, Endologix, EPIC Diagnostics, St. Jude Medical, Tenex Health

Number of Accounts gained: 6

Services: Marketing strategy and planning, brand development, product launches, digital and interactive media, Web design, online medical education, digital selling applications, multimedia production, advertising, direct marketing, DTC, PTC, patient education, trade show promotion.


Featured Work

Description: The Plex-ID System is transforming patient care by enabling clinicians to identify and characterize microbes both uniquely and broadly. The ad draws a sharp contrast between traditional process-of-elimination diagnostics and the Plex-ID's innovative method. In fact, the ad illustrates the contrast quickly and simply, just like the Plex-ID System itself.

Creative/Account Team: Lead Creative: Gary Frederickson; Account Team: Katherine Wiseman, Jon Hermie

Why this ad is special: This creative defines the benefit of a highly technical solution in clear, simple terms. It differentiates the quick and specific way that Plex-ID identifies pathogens compared to traditional process-of-elimination diagnostics. The ad also positions this breakthrough as a new category, a new way of thinking, and a new clinical advantage.